Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.64
NAS:ARAY's Cash-to-Debt is ranked lower than
71% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. NAS:ARAY: 0.64 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ARAY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.64  Med: N/A Max: No Debt
Current: 0.64
Equity-to-Asset 0.11
NAS:ARAY's Equity-to-Asset is ranked lower than
90% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. NAS:ARAY: 0.11 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ARAY' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.65  Med: 0.38 Max: 0.69
Current: 0.11
-0.65
0.69
Interest Coverage N/A
NAS:ARAY's Interest Coverage is ranked higher than
71% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: 93.54 vs. NAS:ARAY: N/A )
Ranked among companies with meaningful Interest Coverage only.
NAS:ARAY' s Interest Coverage Range Over the Past 10 Years
Min: 88.63  Med: N/A Max: N/A
Current: N/A
Piotroski F-Score: 4
Altman Z-Score: 0.26
Beneish M-Score: -2.55
WACC vs ROIC
12.23%
-10.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -2.37
NAS:ARAY's Operating Margin % is ranked lower than
57% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. NAS:ARAY: -2.37 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ARAY' s Operating Margin % Range Over the Past 10 Years
Min: -25.53  Med: -4.98 Max: 1.28
Current: -2.37
-25.53
1.28
Net Margin % -6.88
NAS:ARAY's Net Margin % is ranked lower than
61% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. NAS:ARAY: -6.88 )
Ranked among companies with meaningful Net Margin % only.
NAS:ARAY' s Net Margin % Range Over the Past 10 Years
Min: -32.67  Med: -8 Max: 2.56
Current: -6.88
-32.67
2.56
ROE % -45.50
NAS:ARAY's ROE % is ranked lower than
76% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. NAS:ARAY: -45.50 )
Ranked among companies with meaningful ROE % only.
NAS:ARAY' s ROE % Range Over the Past 10 Years
Min: -68.25  Med: -29.53 Max: 4.2
Current: -45.5
-68.25
4.2
ROA % -5.67
NAS:ARAY's ROA % is ranked lower than
57% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. NAS:ARAY: -5.67 )
Ranked among companies with meaningful ROA % only.
NAS:ARAY' s ROA % Range Over the Past 10 Years
Min: -21.75  Med: -6.38 Max: 1.72
Current: -5.67
-21.75
1.72
ROC (Joel Greenblatt) % -15.56
NAS:ARAY's ROC (Joel Greenblatt) % is ranked lower than
58% of the 288 Companies
in the Global Medical Devices industry.

( Industry Median: 4.02 vs. NAS:ARAY: -15.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ARAY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -207.15  Med: -27.28 Max: 31.27
Current: -15.56
-207.15
31.27
3-Year Revenue Growth Rate 4.70
NAS:ARAY's 3-Year Revenue Growth Rate is ranked higher than
51% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. NAS:ARAY: 4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ARAY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.9  Med: 5.9 Max: 134.9
Current: 4.7
-6.9
134.9
3-Year EPS without NRI Growth Rate -37.80
NAS:ARAY's 3-Year EPS without NRI Growth Rate is ranked lower than
90% of the 197 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. NAS:ARAY: -37.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ARAY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37.8  Med: 6.75 Max: 91.3
Current: -37.8
-37.8
91.3
GuruFocus has detected 2 Warning Signs with Accuray Inc $NAS:ARAY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ARAY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ARAY Guru Trades in Q1 2016

Jim Simons 2,781,400 sh (+22.23%)
Chuck Royce 1,999,500 sh (+15.25%)
Paul Tudor Jones Sold Out
PRIMECAP Management 8,544,500 sh (-0.69%)
Steven Cohen 1,640,800 sh (-13.32%)
» More
Q2 2016

ARAY Guru Trades in Q2 2016

Paul Tudor Jones 32,005 sh (New)
Jim Simons 3,319,000 sh (+19.33%)
PRIMECAP Management 8,523,000 sh (-0.25%)
Chuck Royce 1,722,000 sh (-13.88%)
Steven Cohen 110,100 sh (-93.29%)
» More
Q3 2016

ARAY Guru Trades in Q3 2016

Steven Cohen 234,100 sh (+112.62%)
Jim Simons 4,286,723 sh (+29.16%)
Steven Cohen 219,800 sh (unchged)
Paul Tudor Jones 31,162 sh (-2.63%)
Chuck Royce 1,618,877 sh (-5.99%)
PRIMECAP Management 7,493,600 sh (-12.08%)
» More
Q4 2016

ARAY Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
Jim Simons 4,207,500 sh (-1.85%)
Chuck Royce 1,572,177 sh (-2.88%)
PRIMECAP Management 5,513,300 sh (-26.43%)
Steven Cohen 122,800 sh (-47.54%)
» More
» Details

Insider Trades

Latest Guru Trades with ARAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NYSE:IVC, NAS:EXAC, NAS:XENT, OTCPK:MZRTF, NAS:ELOS, NAS:AXGN, NAS:VRAY, NAS:TCMD, NAS:CUTR, NYSE:CRY, NAS:GNMK, NAS:RTIX, OTCPK:IPDQF, NAS:OBLN, AMEX:CVRS, NAS:IRIX, NAS:PAVM, NAS:NVCN, NAS:ACRX, NAS:OFIX » details
Traded in other countries:XEJ.Germany,
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Its products includes the CyberKnife Systems and the TomoTherapy Systems.

Accuray Inc was incorporated in California in 1990 and commenced operations in 1992. The Company was reincorporated in 2007 in Delaware. The Company is a radiation oncology company. It develops, manufactures, sells and supports precise treatment solutions. The Company's technologies are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy and image guided radiation therapy and adaptive radiation therapy. It operates in Europe, Middle East, India and Africa, Asia Pacific and Japan. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. The CyberKnife Systems are fully robotic stereotactic radiosurgery systems, or SRS and stereotactic body radiation therapy systems, or SBRT used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimeter accuracy while patients breathe normally. Treatment with the CyberKnife Systems requires no anesthesia, and can be performed in one to five staged treatment sessions on an outpatient basis. In addition, the CyberKnife Systems are designed to minimize many of the risks and complications that are associated with other treatment options. The CyberKnife Systems include: the CyberKnife G4, which includes the Fixed collimator; CyberKnife VSI System, which includes the Fixed and Iris collimators and the new CyberKnife M6 Series System, that comes in configurations that have the option of Fixed collimator, Iris collimator, and a MultiLeaf collimator, or MLC. The TomoTherapy Systems are used to treat cancers and tumors, and enable efficient daily imaging to ensure the accuracy of the patient position before each treatment delivery. The TomoTherapy Systems operate on ring gantries and combine integrated CT imaging with intensity modulated radiation therapy or IMRT, which is designed to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The TomoTherapy Systems include the Hi-Art System, delivering CT-guided, helical IMRT; the TomoHD System, which includes both the TomoHelicalTM and TomoDirectTM treatment modalities and the Tomo H TM Series Systems that come in configuration options of TomoHTM, TomoHD and TomoHDATM and which includes one or more options such as TomoHelicalTM, TomoDirectTM, High Performance VoLo TM Planning and TomoEdge Dynamic Jaws. Its competitors are Elekta AB and Varian Medical Systems, Inc, Mitsubishi Heavy Industries, BrainLAB AG, and ViewRay Inc.

Ratios

vs
industry
vs
history
PB Ratio 8.41
ARAY's PB Ratio is ranked lower than
86% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.35 vs. ARAY: 8.41 )
Ranked among companies with meaningful PB Ratio only.
ARAY' s PB Ratio Range Over the Past 10 Years
Min: 1.1  Med: 3.64 Max: 11.51
Current: 8.41
1.1
11.51
PS Ratio 1.05
ARAY's PS Ratio is ranked higher than
78% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.31 vs. ARAY: 1.05 )
Ranked among companies with meaningful PS Ratio only.
ARAY' s PS Ratio Range Over the Past 10 Years
Min: 0.8  Med: 1.53 Max: 6.38
Current: 1.05
0.8
6.38
Price-to-Operating-Cash-Flow 177.78
ARAY's Price-to-Operating-Cash-Flow is ranked lower than
99% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. ARAY: 177.78 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ARAY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.6  Med: 55.08 Max: 9400
Current: 177.78
11.6
9400
EV-to-EBIT -51.72
ARAY's EV-to-EBIT is ranked lower than
99.99% of the 162 Companies
in the Global Medical Devices industry.

( Industry Median: 23.96 vs. ARAY: -51.72 )
Ranked among companies with meaningful EV-to-EBIT only.
ARAY' s EV-to-EBIT Range Over the Past 10 Years
Min: -297.8  Med: -8.95 Max: 1222.2
Current: -51.72
-297.8
1222.2
EV-to-EBITDA 47.75
ARAY's EV-to-EBITDA is ranked lower than
85% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 17.54 vs. ARAY: 47.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -666.8  Med: 27.9 Max: 1894.8
Current: 47.75
-666.8
1894.8
Current Ratio 1.76
ARAY's Current Ratio is ranked lower than
66% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. ARAY: 1.76 )
Ranked among companies with meaningful Current Ratio only.
ARAY' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.92 Max: 3.13
Current: 1.76
0.92
3.13
Quick Ratio 1.11
ARAY's Quick Ratio is ranked lower than
71% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. ARAY: 1.11 )
Ranked among companies with meaningful Quick Ratio only.
ARAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.72  Med: 1.46 Max: 2.67
Current: 1.11
0.72
2.67
Days Inventory 184.30
ARAY's Days Inventory is ranked lower than
72% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 125.58 vs. ARAY: 184.30 )
Ranked among companies with meaningful Days Inventory only.
ARAY' s Days Inventory Range Over the Past 10 Years
Min: 70.63  Med: 128.43 Max: 199.92
Current: 184.3
70.63
199.92
Days Sales Outstanding 69.90
ARAY's Days Sales Outstanding is ranked lower than
53% of the 240 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. ARAY: 69.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.26  Med: 61.53 Max: 101.57
Current: 69.9
26.26
101.57
Days Payable 40.04
ARAY's Days Payable is ranked lower than
70% of the 227 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. ARAY: 40.04 )
Ranked among companies with meaningful Days Payable only.
ARAY' s Days Payable Range Over the Past 10 Years
Min: 20.39  Med: 29.32 Max: 122.61
Current: 40.04
20.39
122.61

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.90
ARAY's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. ARAY: -2.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARAY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -66.2  Med: -8.55 Max: -2.8
Current: -2.9
-66.2
-2.8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.69
ARAY's Price-to-Median-PS-Value is ranked higher than
74% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 1.07 vs. ARAY: 0.69 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARAY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.03 Max: 3.59
Current: 0.69
0.54
3.59
Earnings Yield (Greenblatt) % -1.93
ARAY's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: -0.81 vs. ARAY: -1.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARAY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 0.8 Max: 2.9
Current: -1.93
0.1
2.9

More Statistics

Revenue (TTM) (Mil) $374.3
EPS (TTM) $ -0.31
Beta2.15
Short Percentage of Float8.39%
52-Week Range $4.45 - 6.39
Shares Outstanding (Mil)82.90
» More Articles for NAS:ARAY

Headlines

Articles On GuruFocus.com
PRIMECAP Sells Portions of 3 Stakes Aug 03 2016 
Context Capital Management's Top Buys in Q2 2015 Jul 15 2015 
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
Weekly CEO Buys Highlight: SONS, OPK, AKS, ARAY, ENH Nov 09 2014 
Weekly CEO Buys Highlight: JMP, SONS, OPK, ARAY, CBNJ Nov 04 2014 
Accuray: Leading the Field Of Radiosurgery Jul 24 2014 
Weekly CEO Buys Highlight: AGNC, WTSLA, ARAY, FSC, SREV Feb 19 2013 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
Accuray Inc. (ARAY) President & CEO Euan Thomson sells 12,500 Shares Mar 11 2011 
Accuray Inc. (ARAY) SVP COO Chris Raanes sells 1,000 Shares Mar 07 2011 

More From Other Websites
ACCURAY INC Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 10 2017
Accuray, Inc. breached its 50 day moving average in a Bearish Manner : ARAY-US : March 7, 2017 Mar 07 2017
Accuray Launches New Cancer Patient Websites Mar 02 2017
Accuray to Present at Cowen and Company 37th Annual Healthcare Conference on March 6, 2017 Feb 21 2017
CyberKnife® System Provides Long-term Disease Control for Prostate Cancer Patients Feb 16 2017
Accuray to Participate in the 2017 RBC Capital Markets Healthcare Conference on February 22, 2017 Feb 13 2017
ACCURAY INC Financials Feb 09 2017
The Accuray Radixact™ System Receives Shonin Approval Feb 08 2017
Accuray, Inc. :ARAY-US: Earnings Analysis: Q2, 2017 By the Numbers : February 7, 2017 Feb 07 2017
ACCURAY INC Files SEC form 10-Q, Quarterly Report Feb 03 2017
Accuray (ARAY) Incurs Wider Loss in Q2, Misses on Revenue Feb 01 2017
Edited Transcript of ARAY earnings conference call or presentation 31-Jan-17 9:30pm GMT Jan 31 2017
Accuray reports 2Q loss Jan 31 2017
Accuray reports 2Q loss Jan 31 2017
Accuray Inc Earnings Call scheduled for 4:30 pm ET today Jan 31 2017
ACCURAY INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jan 31 2017
Accuray Grows Second Quarter Gross Orders 17%; Backlog Up 16% YoY Jan 31 2017
Q2 2017 Accuray Inc Earnings Release - After Market Close Jan 31 2017
Why Earnings Season Could Be Great for Accuray (ARAY) Jan 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)